Pharmafile Logo
T40 2022 Cover
Diversity, Equity and Inclusion
Communiqué 53 Cover Image
- PMLiVE

Ebola

- PMLiVE

Merck’s adult-specific pneumococcal vaccine shows promise in late-stage study

There are more than 100 types of pneumococcal bacteria, which can affect adults differently than children

- PMLiVE

WHO reveals ‘extensive’ worldwide overuse of antibiotics during COVID-19 pandemic

Findings from the report reveal factors that could have contributed to the spread of antimicrobial resistance

- PMLiVE

World Health Organization prequalifies simplified oral cholera vaccine Euvichol-S

The acute diarrhoeal illness was reported to affect around 473,000 people in 2022

- PMLiVE

Merck acquires Abceutics in deal worth $208m to improve safety of ADCs

As part of the deal, Merck will gain access to the start-up’s payload selectivity enhancer technology

- PMLiVE

World Health Organization launches AI-powered digital health assistant for public health

SARAH has been launched in alignment with World Health Day’s theme, ‘My Health, My Right’

- PMLiVE

Merck’s Keytruda regimen granted EC approval for expanded lung cancer use

The approval represents the sixth lung cancer indication for the anti-PD-1 therapy in Europe

- PMLiVE

Merck’s Winrevair granted FDA approval to treat pulmonary arterial hypertension in adults

The rare blood vessel disorder affects approximately 500 to 1,000 people in the US every year

- PMLiVE

Merck’s pneumococcal vaccine candidate for adults shows promise in late-stage studies

V116 is designed to address the strains responsible for the majority of adult pneumococcal disease

- PMLiVE

Merck presents positive phase 3 data for Keytruda plus CRT in advanced cervical cancer

According to WHO, cervical cancer is the fourth most common cancer in women globally

- PMLiVE

WHO reveals growing global cancer burden in line with World Cancer Day

The three most commonly occurring cancers in 2022 were lung, breast and colorectal cancer

- PMLiVE

Merck shares positive results for Keytruda in phase 3 bladder cancer study

About 83,000 people in the US will be diagnosed with bladder cancer in 2024

- PMLiVE

Merck shares positive results for Keytruda in phase 3 kidney cancer study

Renal cell carcinoma accounts for approximately 90% of all kidney cancer diagnoses

Subscribe to our email news alerts

Latest jobs from #PharmaRole

Latest content

Latest intelligence

Quick links